ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
18 announcements with these filters
H1 FY27 revenue of ₹667 Cr was slightly below ₹680 Cr a year ago. Management blamed a one-month government rate-contract delay and reiterated 25% FY27 growth guidance.
Molbio Diagnostics filed CRISIL's monitoring agency report on IPO proceeds utilisation for the quarter ended 30 September 2026. The report states no deviation from the issue objects.
Q2 FY27 revenue ₹259 Cr (-55% YoY), PAT ₹7.7 Cr (-93%). H1 FY27 revenue ₹667 Cr (-2%), PAT ₹60 Cr (-27%). Management reiterates 25% FY27 topline growth target.
Molbio Diagnostics Ltd reported revenue from operations of ₹259 Cr (-55.4% YoY) and net profit of ₹7.7 Cr (-92.8% YoY) for Q2 FY27.
Molbio Diagnostics' Board is scheduled for November 5, 2026, to approve Q1 and H1 results. Trading window stays closed until 48 hours post-declaration.
Molbio Diagnostics responded to NSE's spurt-in-volume query, stating the movement is purely market-driven. No pending price-sensitive information is slated for disclosure.
Molbio Diagnostics Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure provides information on promoter and public shareholding structures.
Kotak Mahindra Mutual Fund acquired 5,70,000 Molbio Diagnostics shares in the open market on 08 October 2026. Its stake crossed 5% to 5.4834%.
Molbio Diagnostics Limited re-appointed M/s. K.S. Kamalakara & Co as Cost Auditors for a 12-month term. The decision was finalized during a board meeting on September 25, 2026.
Molbio Diagnostics Limited has re-appointed M/s K. S. Kamalakara & Co as its Cost Auditor for the financial year 2026-27. The Board approved the appointment today.
India Business Excellence Fund III sold 30,00,000 shares (2.60% stake) of Molbio Diagnostics Limited. The transaction was executed via open market on September 23, 2026.
Molbio reported Q1 FY27 revenue of ₹408 Cr with a 25% EBITDA margin. Strategy focuses on expanding Truenat's global footprint and integrating digital pathology via OptraScan.
Molbio Diagnostics informed exchanges that its CIN changed from U33125GA2000PLC002909 to L33125GA2000PLC002909 post-listing. The MCA status was updated from Unlisted to Listed.
Molbio Diagnostics listed on Aug 17, 2026. Q1 FY27 saw Total Income of ₹411.5 Cr and EBITDA of ₹103.7 Cr, transitioning from a loss in Q1 FY26 driven by higher test-kit consumption.
Molbio Diagnostics reported Q1 FY27 total income of ₹411.48 Cr and PAT of ₹52.74 Cr, a swing from prior-year losses. Growth was driven by Truenat test-kit volume and deferred Gulf export orders.
Molbio Diagnostics Ltd reported revenue from operations of ₹408.4 Cr (+309.6% YoY) and net profit of ₹52.7 Cr for Q1 FY27.
Molbio Diagnostics Limited scheduled a board meeting for September 5, 2026, to approve the unaudited standalone and consolidated financial results for the June 2026 quarter.
Molbio Diagnostics Limited has designated Mr. Darshan Raghunath Karekar as the company's Compliance Officer under the SEBI (Prohibition of Insider Trading) Regulations, 2015.